Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.

about

Fourteen-Year Anti-TNF Therapy in Crohn's Disease Patients: Clinical Characteristics and Predictive Factors.

Item

http://www.wikidata.org/entity/Q47361114

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Fourteen-Year Anti-TNF Therapy ...... istics and Predictive Factors.

@en

Fourteen-Year Anti-TNF Therapy ...... istics and Predictive Factors.

@nl

type

Item

label

Fourteen-Year Anti-TNF Therapy ...... istics and Predictive Factors.

@en

Fourteen-Year Anti-TNF Therapy ...... istics and Predictive Factors.

@nl

prefLabel

Fourteen-Year Anti-TNF Therapy ...... istics and Predictive Factors.

@en

Fourteen-Year Anti-TNF Therapy ...... istics and Predictive Factors.

@nl

P1476

Fourteen-Year Anti-TNF Therapy ...... istics and Predictive Factors.

@en

P2093

Aisaku Osamura

http://www.w3.org/2001/XMLSchema#string

Yasuo Suzuki

http://www.w3.org/2001/XMLSchema#string

P2860

Early development of stricturing or penetrating pattern in Crohn's disease is influenced by disease location, number of flares, and smoking but not by NOD2/CARD15 genotype.

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health

Review article: loss of response to anti-TNF treatments in Crohn's disease.

Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.

Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD.

Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms.

Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease: A Prospective, Randomized Trial.

C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.

Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.

Infliximab, azathioprine, or combination therapy for Crohn's disease

P2888

s10620-017-4846-x

P304

204-208

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10620-017-4846-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29209921

http://www.w3.org/2001/XMLSchema#string

P921

TNF inhibitor